Objective-To investigate the association of plasma phylloquinone concentrations with coronary artery calcification (CAC) and vascular calcification. Approach and results-In a prospective cohort of 508 postmenopausal women, plasma phylloquinone concentrations were measured by high-pressure liquid chromatography. Calcification was measured in the coronary arteries, aortic valve, mitral valve, and thoracic aorta by multidetector computed tomography. To combine these calcification scores, we dichotomized each of the 4 areas into present or absent. Because of the continuous measurement of CAC, we categorized this as calcification present if Agatston score was >0, and calcification score was calculated as the sum of the calcified areas. Multivariate-adjusted prevalence ratios and odds ratios were estimated using Poisson regression and multinomial logistic regression. After 8.5 years of follow-up, 22% of the women had no calcification, whereas 5% had calcification in all measured areas. Detectable phylloquinone concentrations were associated with increased CAC compared with nondetectable phylloquinone concentrations with a prevalence ratio of 1.34 (95% confidence interval, 1. 
V itamin K is a fat-soluble vitamin that occurs in 2 biologically active forms: vitamin K 1 (phylloquinone) and vitamin K 2 (menaquinones). Phylloquinone is present in green, leafy vegetables and certain vegetable oils, 1 although menaquinones are mostly found in animal products such as meat and fermented foods such as cheese and buttermilk. 2 Vitamin K acts as a cofactor for the enzyme γ-glutamyl carboxylase, catalyzing the carboxylation of specific glutamic acid residues (Glu) to form γ-carboxyglutamate (Gla) in vitamin K-dependent proteins. Matrix Gla protein is a vitamin K-dependent protein and an inhibitor of vascular calcification. 3 It has been proposed that vitamin K could, therefore, reduce coronary artery calcification (CAC) and risk of cardiovascular disease through the carboxylation of matrix Gla protein.
Results from observational studies investigating relationships of vitamin K intake with CAC and risk of cardiovascular disease are, however, inconsistent. Observational studies that both investigate relationships of phylloquinone and menaquinone intake consistently showed that high intakes of menaquinone are associated with reduced arterial calcification and cardiovascular disease risk. [4] [5] [6] However, for phylloquinone intake, these observational studies do not show associations with CAC or incidence of cardiovascular disease. [4] [5] [6] Nevertheless, intervention studies showed improved vascular elasticity and reduced progression of coronary calcification after phylloquinone supplementation. 7, 8 This discrepancy could be explained by dose differences between observational studies (mean phylloquinone intake of 115-257 μg/d) and intervention studies (supplements with 500 μg/d or 1 mg/d). Another explanation could be the low relative validity of phylloquinone intake as estimated by food frequency questionnaires. 6 Because of this limitation, results for phylloquinone intake need to be confirmed by results of other markers of phylloquinone exposure. Circulating plasma phylloquinone concentrations may be a better measure for phylloquinone intake than phylloquinone intake measured by food frequency questionnaires. A recent case-cohort study showed that low phylloquinone concentrations could be associated with greater CAC progression. 9 Based on these results, we hypothesized that high phylloquinone concentrations are associated with less calcification. Mechanistically, there seems to be some overlap between coronary and aortic calcifications with heart valve calcification because both pathologies share some risk factors. Theoretically, treatment for aortic and coronary calcifications would be effective for valve calcifications as well. 10 We, therefore, investigated the association of plasma phylloquinone concentrations with CAC and vascular calcification among 508 postmenopausal healthy women.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
Baseline characteristics of the study population dichotomized by detectable and nondetectable phylloquinone concentrations are presented in Table 1 . The mean (±SD) follow-up time was 8.5 (±1.3) years. Of these women, 42% had CAC, 22% had aortic valve calcification, 11% had mitral valve calcification, and 62% had aortic calcification. No calcification measures were available at baseline. Women with detectable phylloquinone concentrations (>lower limit of detection) at baseline were more likely to be older and had a higher body mass index, cholesterol ratio, and phylloquinone intake but were less likely to be smokers. No significant differences were noted in baseline blood pressure, total cholesterol levels and energy, or menaquinone intake between the 2 groups.
Detectable phylloquinone concentrations were associated with more CAC at follow-up compared with those with nondetectable phylloquinone concentrations with a prevalence ratio of 1.42 (95% confidence interval [CI], 1.7-1.87; P=0.01) in crude analyses. This association attenuated to a prevalence ratio of 1.34 (95% CI, 1.01-1.77; P=0.04) after adjustment for follow-up time, age, smoking, and body mass index. Adding non-high-density lipoprotein (HDL) ratio and cholesterollowering drug use into the model did not materially change the results (prevalence ratio, 1.33; 95% CI, 1.01-1.77; P=0.04). Table 2 shows the association of detectable phylloquinone concentrations divided into 2 equal groups versus nondetectable phylloquinone with follow-up CAC. The low detectable phylloquinone group was associated with increased CAC with a prevalence ratio of 1.32 (95% CI, 0.99-1.76; P=0.06) and the high detectable phylloquinone group with a prevalence ratio of 1.36 (95% CI, 1.02-1.81; P=0.04; P for trend, 0.07) after full adjustment. Similar, but slightly attenuated results were observed additionally adjusting for non-HDL cholesterol, cholesterol-lowering drug use, and hypertension, with prevalence ratios of 1.29 (95% CI, 0.97-1.73; P=0.09) and 1.30 (95% CI, 0.98-1.71; P=0.07; P for trend, 0.13) for the 2 detectable phylloquinone concentration groups, respectively.
In addition, phylloquinone concentration was associated with more calcification at follow-up with an odds ratio (OR) (no versus Agatston score 0-400) of 1.83 (95% CI, 1.09-3.08; P=0.02) and an OR (no versus Agatston score ≥400) of 3.74 (95% CI,0.82-16.99; P=0.09) after adjustment.
Baseline phylloquinone concentrations were not associated with the number of calcified areas at follow-up with an OR (no versus ≥ 3 areas calcifications) of 1.60 (95% CI, 0.65-3.99; P=0.31) after adjustment ( 
Discussion
In contrast to our hypothesis, we did not demonstrate that detectable phylloquinone concentrations were associated with a reduced risk of vascular calcification. Instead, detectable concentrations seemed to be associated with increased prevalence of CAC.
Our hypothesis was based on 2 intervention studies showing improved vascular elasticity and reduced progression of coronary calcification after phylloquinone supplementation 7, 8 and a case-cohort study showing similar associations. 9 Unexpectedly, we found higher prevalence of CAC in participants with detectable phylloquinone concentrations in the present study. The previously published case-cohort study 9 observed a nonsignificant association between low phylloquinone concentrations (<1.0 nmol/L) and extreme CAC progression (OR, 1.34; 95% CI, 0.94-1.90; P=0.11). In our study, detectable concentrations seemed to be associated with increased prevalence of CAC. This contradiction may be caused by the differences in study design between our study and the case-cohort study. We investigated the association between phylloquinone concentrations with the prevalence of CAC within a healthy population, whereas Shea et al 9 compared people with extreme CAC progression with a healthy reference group. The contrast between the 2 groups is, therefore, much smaller in our study. In addition, our study was limited to investigating prevalence of CAC. Because we did not measure progression, comparing the 2 studies is difficult. However, these findings show that the study of associations between phylloquinone concentrations and CAC may oversimplify the complexity of the underlying mechanisms.
Our results are inconsistent with previous intervention studies, but the phylloquinone dosages that were used 7, 8 were ≥2× to 4× higher than the mean habitual dietary phylloquinone intake in observational studies. It is possible that the protective effect of phylloquinone on CAC can only be reached with supplementary dosages and not with dietary intake.
In a previous study in the same study population, after full adjustment a nonsignificant trend was observed toward an increased risk with a relative risk of 1.17 (95% CI, 0.96-1.42; P for trend=0.11) for the highest versus lowest quartile of phylloquinone intake. 4 This is in concordance with the results we found in the present study. Therefore, our assumption that our results on phylloquinone intake were driven by the low relative validity of phylloquinone intake as estimated by the food frequency questionnaires might be incorrect because we now observed the same direction of effect in plasma measurements.
Alternatively, participants with CAC at baseline may have had characteristics or risk factors that influenced overall nutritional status, which are reflected in the plasma phylloquinone concentrations. 11 A possible explanation for this unexpected observation is that plasma phylloquinone may be a marker of an unmeasured biochemical or genetic risk factor for calcification. For example, the minor allele of VKORC1 rs8050894 (G) and the major allele of VKORC1 rs7294 (G) are associated with higher phylloquinone concentrations. 12 These alleles are linked and have been reported to be part of haplotype sequences that are associated with decreased warfarin dose requirements. 13, 14 Furthermore, VKORC1 haplotypes that reduce the activity of the VKORC1 enzyme have been shown to be associated with a significant higher risk of vascular calcification in rats 15 and aortic calcification in humans. 16 Hence, it is possible that similar polymorphisms in genes involved in the phylloquinone metabolism may result in higher phylloquinone status because of reduced phylloquinone recycling or metabolism. Furthermore, it is also possible that higher phylloquinone concentrations are caused by disturbed phylloquinone transport or cellular phylloquinone uptake. However, these potential mechanisms have not been investigated yet.
Strengths of this study include the prospective study design, measurement of vascular calcification, and plasma phylloquinone concentrations in healthy women. Nevertheless, our study has certain limitations to consider. Circulating phylloquinone concentrations are thought to reflect overall status but are highly correlated with triglycerides because of being transported on triglyceride lipoproteins. 17 Unfortunately, data about triglyceride concentrations were only available in a subsample of 63 women. In this group, we adjusted for triglyceride concentrations that did not change the results (after adjustment, the prevalence ratio of 1.30 attenuated to a prevalence ratio of 1.27). Because we had limited data on triglyceride concentrations, we used non-HDL cholesterol as a proxy because this correlated with triglyceride concentrations (r=0.41). 18 Adjusting for non-HDL in an additional analysis did not materially change our results. In addition, results did not change after excluding women with high phylloquinone concentrations (>2.0 nmol/L) as a result of high lipid levels. Furthermore, a previous study showed that circulating triglycerides were not associated with phylloquinone concentrations. 19 Furthermore, phylloquinone concentrations reflect recent intakes. 20, 21 Although adjusting for time since last meal did not affect our results, no information on the content of the last meal before blood sampling was available. Therefore, it could be that the use of a nonfasting plasma phylloquinone measure as a marker for long-term vitamin K status affected our results. Unfortunately, this study did not measure baseline vascular calcification, which precludes evaluation of the predictive value of phylloquinone concentrations on progression of vascular calcification.
Taken together, this study shows that a normal phylloquinone status is not associated with reduced vascular calcification but instead seemed to be associated with higher CAC prevalence. Additional research is required to confirm our findings and to investigate possible underlying mechanisms for these associations.
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